-
公开(公告)号:US08846664B2
公开(公告)日:2014-09-30
申请号:US12998634
申请日:2009-11-12
申请人: Wei-Sheng Huang , R. Mathew Thomas
发明人: Wei-Sheng Huang , R. Mathew Thomas
IPC分类号: A01N43/62 , A61K31/55 , A61K31/497 , C07D491/00 , C07D513/00 , C07D515/00 , C07D471/00 , C07D487/00 , C07D495/00 , C07D497/00 , A61K9/48 , C07D471/04 , A61K9/28 , A61K47/10 , A61K9/20 , A61K9/00 , C07D487/04
CPC分类号: C07D487/04 , A61K9/0019 , A61K9/008 , A61K9/2018 , A61K9/2866 , A61K9/4858 , A61K47/10 , C07D471/04
摘要: This invention relates to compounds of the general formula: in which the variable groups are as defined herein, and to their preparation and use.
摘要翻译: 本发明涉及以下通式的化合物:其中可变基团如本文所定义,及其制备和用途。
-
52.
公开(公告)号:US20140045826A1
公开(公告)日:2014-02-13
申请号:US14009565
申请日:2012-04-06
IPC分类号: C07D487/04 , C07D471/04
CPC分类号: C07D487/04 , A61K31/495 , C07D471/04
摘要: The invention discloses methods and compositions for treating or preventing neurodegenerative disease by administering a compound of Formula I: or a pharmaceutically acceptable salt, solvate or hydrate thereof, wherein the variables are defined as herein.
摘要翻译: 本发明公开了通过给予式I化合物或其药学上可接受的盐,溶剂合物或水合物来治疗或预防神经变性疾病的方法和组合物,其中变量如本文所定义。
-
公开(公告)号:US20130018046A1
公开(公告)日:2013-01-17
申请号:US13614838
申请日:2012-09-13
申请人: Yihan Wang , Xiaotian Zhu , Rajeswari Sundaramoorthi , Wei-Sheng Huang , Dong Zou , R. Mathew Thomas , Jiwei Qi , Jan Antoinette C. Romero , David C. Dalgarno , William C. Shakespeare , Tomi K. Sawyer , Chester A. Metcalf, III
发明人: Yihan Wang , Xiaotian Zhu , Rajeswari Sundaramoorthi , Wei-Sheng Huang , Dong Zou , R. Mathew Thomas , Jiwei Qi , Jan Antoinette C. Romero , David C. Dalgarno , William C. Shakespeare , Tomi K. Sawyer , Chester A. Metcalf, III
IPC分类号: A61K31/4439 , C07D403/12 , A61K31/506 , C07D401/12 , A61K31/496 , C07D471/04 , A61K31/4375 , C07D413/12 , A61K31/4725 , A61K31/502 , A61K31/497 , C07D498/04 , A61K31/5383 , A61K31/551 , A61K31/5377 , A61K31/53 , A61P35/00 , C07D401/14
CPC分类号: C07D213/56 , C07D213/73 , C07D213/75 , C07D213/78 , C07D217/14 , C07D217/22 , C07D237/20 , C07D237/28 , C07D239/26 , C07D241/12 , C07D241/20 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/06 , C07D413/12 , C07D417/12 , C07D471/04
摘要: This invention relates to compounds of the general formula: in which the variable groups are as defined herein, and to their preparation and use.
-
公开(公告)号:US08278307B2
公开(公告)日:2012-10-02
申请号:US12227130
申请日:2007-05-08
申请人: William C. Shakespeare , Wei-Sheng Huang , David C. Dalgarno , Xiaotian Zhu , R. Mathew Thomas , Yihan Wang , Jiwei Qi , Rajeswari Sundaramoorthi , Dong Zou , Chester A. Metcalf, III , Tomi K. Sawyer , Jan Antoinette C. Romero
发明人: William C. Shakespeare , Wei-Sheng Huang , David C. Dalgarno , Xiaotian Zhu , R. Mathew Thomas , Yihan Wang , Jiwei Qi , Rajeswari Sundaramoorthi , Dong Zou , Chester A. Metcalf, III , Tomi K. Sawyer , Jan Antoinette C. Romero
IPC分类号: A61K31/496 , A61K31/4178 , C07D403/12
CPC分类号: C07D231/12 , C07D233/64 , C07D233/90 , C07D277/40 , C07D403/12 , C07D403/14 , C07D417/12 , C07D417/14
摘要: This invention relates to compounds of the general formula: in which the variable groups are as defined herein, and to their preparation and use.
摘要翻译: 本发明涉及以下通式的化合物:其中可变基团如本文所定义,以及其制备和用途。
-
公开(公告)号:US07019139B2
公开(公告)日:2006-03-28
申请号:US10715794
申请日:2003-11-17
申请人: Chester A. Metcalf, III , William C. Shakespeare , Tomi K. Sawyer , Yihan Wang , Regine Bohacek , Rajeswari Sundaramoorthi
发明人: Chester A. Metcalf, III , William C. Shakespeare , Tomi K. Sawyer , Yihan Wang , Regine Bohacek , Rajeswari Sundaramoorthi
IPC分类号: C07D221/18 , C07D215/16
CPC分类号: C07F9/65583 , A61K31/47 , A61K45/06 , C07F9/4012 , C07F9/58 , C07F9/60 , A61K2300/00
摘要: The invention relates to compounds of the general formula (and pharmaceutically acceptable derivatives thereof): in which RA, RB, RC, RD, R5, R7, R9, R9a, AK, p, q, r and X are as defined herein, and to their preparation and use.
摘要翻译: 本发明涉及通式(及其药学上可接受的衍生物)的化合物:其中R A,R B,R B,R C,R R 5,R 9,R 9,R 9,R 9,R 9,R 9, ,p,q,r和X如本文所定义,以及它们的制备和用途。
-
公开(公告)号:US20040152671A1
公开(公告)日:2004-08-05
申请号:US10716239
申请日:2003-11-17
发明人: Yihan Wang , Chester A. Metcalf III , William C. Shakespeare , Tomi K. Sawyer , Regine Bohacek , Rajeswari Sundaramoorthi
IPC分类号: A61K031/675
CPC分类号: C07F9/3821 , C07F9/4012 , C07F9/60 , C07F9/65583
摘要: This invention relates to compounds of the general formula: 1 in which RA, RB, RC and RD are as defined herein, and to their preparation and use.
摘要翻译: 本发明涉及下列通式的化合物:其中R A,R B,R C和R D如本文所定义,以及其制备和用途。
-
公开(公告)号:US5981262A
公开(公告)日:1999-11-09
申请号:US596319
申请日:1996-01-31
申请人: Joan Brugge , Jay Morganstern , Lily Shiue , Lynne Zydowsky , Mark Zoller , Anthony Pawson
发明人: Joan Brugge , Jay Morganstern , Lily Shiue , Lynne Zydowsky , Mark Zoller , Anthony Pawson
IPC分类号: C12N15/09 , A61K38/00 , C12N1/11 , C12N1/21 , C12N5/10 , C12N9/12 , C12P21/02 , C12R1/19 , C12N1/20 , C07H21/04 , C12P21/06
CPC分类号: C12N9/1205 , A61K38/00
摘要: The molecular cloning of humansyk DNA, compositions containing same and uses thereof are disclosed.
摘要翻译: PCT No.PCT / US94 / 04540 Sec。 371日期1996年1月31日 102(e)日期1996年1月31日PCT 1994年4月25日PCT公布。 公开号WO94 / 25565 日期:1994年11月10日公开了人类DNA的分子克隆,含有其的组合物及其用途。
-
公开(公告)号:US20220033392A1
公开(公告)日:2022-02-03
申请号:US17226531
申请日:2021-04-09
发明人: Nicholas E. Bencivenga , David C. Dalgarno , Joseph M. Gozgit , Wei-Sheng Huang , Anna Kohlmann , Feng Li , Jiwei Qi , William C. Shakespeare , Ranny M. Thomas , Yihan Wang , Xiaotian Zhu
IPC分类号: C07D417/12 , C07D417/04 , C07D277/46
摘要: The invention relates to c-Kit inhibitors useful in the treatment of cancers, and other serine-threonine kinase mediated diseases, having the Formula: wherein A, L, R1, R2, R3, and n are described herein.
-
公开(公告)号:US20210323976A1
公开(公告)日:2021-10-21
申请号:US15573211
申请日:2016-05-12
发明人: Wei-Sheng Huang , Tianjun Zhou , Willmen W. Youngsaye , William C. Shakespeare , Alexey V. Ishchenko , David C. Dalgarno
IPC分类号: C07D498/04 , C07D487/04 , C07D471/04 , C07D491/147 , C07D403/04
摘要: Compounds and pharmaceutical compositions that modulate kinase activity, including mutant EGFR and mutant HER2 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including mutant EGFRand mutant HER2 activity, are described herein.
-
公开(公告)号:US20210309640A1
公开(公告)日:2021-10-07
申请号:US17055164
申请日:2019-05-13
发明人: Landon J. DURAK , Marianne Langston , Pradeep Kumar Sharma , Thai Hiep Nguyen , Shuanglian Li , Xiaoguang Zhang
IPC分类号: C07D403/04 , A61P35/00
摘要: The present disclosure relates to pharmaceutical salts and polymorphic forms of forms of pyrimidine derivatives that have inhibitory activities against mutant epidermal growth factor receptor (EGFR). The present disclosure further relates to the processes for the preparation of the pyrimidine derivatives and to the pharmaceutical salts and the polymorphic forms of the pyrimidine derivatives.
-
-
-
-
-
-
-
-
-